## Supplementary Figure S1




Fig. S1 Vascular endothelial cells participate in sorafenib-induced hyper-keratosis in human primary keratinocytes.

**a** Human primary keratinocytes were treated with 0-15  $\mu$ M sorafenib for 24 h. Cell survival rate was detected by SRB colorimetric assay (N = 3). **b**, **c** Human primary keratinocytes were treated with 0-15  $\mu$ M sorafenib for 24 h. The transcription levels of proliferation markers (**b**) and differentiation markers (**c**) were measured by RT-qPCR (N = 3). **d** HUVECs were treated with 0-15  $\mu$ M sorafenib for 72 h. Cell survival rate was detected by SRB colorimetric assay (N = 3). **e** Human primary keratinocytes were treated with supernatants from HUVECs exposed to 0 or 15  $\mu$ M sorafenib (CdM<sup>CTRL</sup> or CdM<sup>SORA</sup>) for 24 h. Cell survival rate was

detected by SRB colorimetric assay (N = 3). **f**, **g** Human primary keratinocytes were treated with supernatants from HUVECs with or without sorafenib exposure (CdM<sup>CTRL</sup> or CdM<sup>SORA</sup>) for 24 h. (**f**) The transcription levels of *KRT5* and *KRT14* were measured by RT-qPCR (N = 3). (**g**) The transcription levels of *KRT1*, *KRT10*, *LORICRIN* and *IVL* were measured by RT-qPCR (N = 3). The results in (**a**), (**b**), (**c**), (**d**), (**e**), (**f**) and (**g**) are presented as the mean  $\pm$  SD. Statistical analyses were performed using unpaired two-tailed Student's t-test in (**f**) and (**g**). Statistical analyses were performed using one-way ANOVA with LSD post hoc test in (**a**) and when comparing the levels of *KRT10* in (**c**) and with Dunn's post hoc test in (**b**), (**d**) and when comparing the levels of *KRT11*, *LORICRIN* and *IVL* in (**c**). \*P < 0.05; \*\*P < 0.01; \*\*\* P < 0.001. SORA, sorafenib; CdM, HUVECs conditional medium; CTRL, control; SRB, sulforhodamine B.